Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCR3-targeted nanobody
- Development stage
- Preclinical
- Lead developer
- Chinese PLA General Hospital
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
CXCR3-targeted nanobody is a preclinical-stage single-domain antibody (nanobody) designed to target and block the C-X-C chemokine receptor type 3 (CXCR3). Developed by researchers at the Chinese PLA General Hospital, this nanobody is being investigated for its therapeutic potential in cardiovascular diseases, specifically atherosclerosis. By blocking the CXCL10-CXCR3 signaling axis, the nanobody inhibits macrophage trained immunity, reverses intraplaque cellular crosstalk, and attenuates atherosclerotic plaque progression. Preclinical studies in mouse models have demonstrated that CXCR3 nanobody blockade significantly reduces aortic lesions, offering a novel approach to cardiovascular immunotherapy.
- Other names
- CXCR3 nanobodyCXCR-3 nanobodyCXCR 3 nanobodyCXCR3-targeted nanobodyCXCR-3-targeted nanobodyCXCR 3-targeted nanobody
02
Targets
CXCL10 (C-X-C Motif Chemokine Ligand 10)CXCL11 (C-X-C motif chemokine ligand 11)CXCL9 (C-X-C motif chemokine ligand 9)CCR3 (C-C chemokine receptor type 3)
Beyond the preview
Go deeper on CXCR3-targeted nanobody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCR3-targeted nanobody.